Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results
Voyager Therapeutics and Sangamo Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
Voyager Therapeutics’ Progress and Momentum Detailed in Recent BioCentury Article
Path to Progress
Novel AAV capsids born from Voyager’s RNA-driven TRACERTM screening platform hold promise to target desired cells and tissues with greater specificity, at lower doses, and with fewer off-target risks than conventional AAV serotypes. TRACER capsids power internal product development and external partnerships with the goal of elevating the field of gene therapy to its highest potential.1
1 Nonnenmacher, et al. “RNA-driven Evolution of AAV Capsid Libraries Identifies Variants with High Transduction Efficiency in Non-Human Primate Central Nervous System.” ASGCT 2021.
Equipped for the Journey
We see each step in our journey as progress toward unlocking the full potential of gene therapy. This is an opportunity to evolve, innovate, and close in on this breakthrough that has enormous promise to change the trajectory of disease and positively alter the lives of millions of people.
In the News
– GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing – – SOD1 ALS gene therapy program on track for development candidate selection by end of year – – Conference call at 4:30 p.m. ET today – LEXINGTON, Mass. , Nov.
CAMBRIDGE, Mass. , Oct. 30, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023 financial and operating results after market close on